Volume 24, Number 3, 471-479, DOI: 10.1007/s11095-006-9172-5

Best Practices for Managing Quality and Safety of Foreign Particles in Orally Inhaled and Nasal Drug Products, and an Evaluation of Clinical Relevance

James Blanchard, James Coleman, Courtney Crim, Claire D’Abreu-Hayling, Lou Fries, Raouf Ghaderi, Barbara Haeberlin, Richard Malcolmson, Stanley Mittelman and Lee Nagao, et al.

View Related Documents

Abstract

The members of IPAC-RS are Aradigm, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Kos, Nektar Therapeutics, Novartis, Novo Nordisk, Pfizer, sanofi aventis, Schering-Plough, and Teva Specialty Pharmaceuticals.

Fulltext Preview

Image of the first page of the fulltext document